Amanote Research
Register
Sign In
Comment on ‘Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: 1-Year Outcomes of a Prospective, Double-Masked Randomised Clinical Trial’
Eye
- United Kingdom
doi 10.1038/eye.2011.18
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Arts
Sensory Systems
Ophthalmology
Humanities
Date
February 25, 2011
Authors
T Fayers
Publisher
Springer Science and Business Media LLC
Related search
Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration
Ophthalmology
Ophthalmology
Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration
Investigative Ophthalmology and Visual Science
Molecular Neuroscience
Ophthalmology
Sensory Systems
Cellular
Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up
Clinical Ophthalmology
Ophthalmology
Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Archives of Ophthalmology
Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine
Medicine
Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data From an Observational Study
Ophthalmology
Ophthalmology
Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration
European Ophthalmic Review
One-Year Outcomes of 1 Dose Versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
Journal of Ophthalmology
Ophthalmology
Comment On: ‘One-Year Real-World Outcomes in Patients Receiving Fixed-Dosing Aflibercept for Neovascular Age-Related Macular Degeneration’
Eye
Medicine
Arts
Sensory Systems
Ophthalmology
Humanities
